177Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?

R adiopharmaceutical therapy (RPT) is established as an innovative, effective, and well-tolerated treatment platform approved for well-differentiated neuroendocrine tumors and advanced prostate cancer (PC) and is being investigated in many other cancers such as breast, lung, and thyroid ( 1 – 3 ), emerging as an essential pillar in oncology. On the basis of several